OCREVUS® (ocrelizumab) Pregnancy Registry
OCREVUS® (ocrelizumab) Pregnancy Registry https://www.ocrevuspregnancyregistry.com/ Do you have multiple sclerosis (MS) and are you pregnant? Then you may be able…
Starting Mayzent Early of Greater Benefit in SPMS, 5-Year Trial Data Show
APRIL 22, 2020 – BY MARISA WEXLER, MS Click HERE to Subscribe for the MS Beacon Newsletter People with secondary progressive…
Stuart Schlossman
Sanofi brain-penetrant BTK inhibitor significantly reduced disease activity in Phase 2 trial in relapsing multiple sclerosis
PRESS RELEASES April 23 2020 Click HERE to Subscribe for the MS Beacon Newsletter Sanofi brain-penetrant BTK inhibitor significantly…
Stuart Schlossman
Shorter Ocrelizumab Infusion Accepted for FDA Review
The FDA has accepted an sBLA for a version of Genentech’s ocrelizumab with a shorter administration time for the treatment…
Stuart Schlossman
Bristol Myers Squibb Expands Patient Support Programs to Help Newly Uninsured Patients in the U.S.
For those in US, P.R and US Virgin Islands Immediate Relief Available April 07, 2020 06:59 AM Eastern Daylight Time…
Stuart Schlossman
FDA Removes Pregnancy Category C Warning From Certain MS Medications
Clinical Neurology News/Neurology Reviews, By Lucas Franki April 2, 2020 https://www.mdedge.com/neurology/article/220153/multiple-sclerosis/fda-removes-pregnancy-category-c-warning-certain-ms The Food and Drug Administration has updated the labels…
Stuart Schlossman
U.S. – FDA Approves Bristol Myers Squibb’s ZEPOSIA® (Ozanimod), a New Oral Treatment for Multiple Sclerosis
In clinical trials, ZEPOSIA demonstrated efficacy on a key clinical marker of disease activity – annualized relapse rate (ARR) – as compared…
Stuart Schlossman
A Look at Your Multiple Sclerosis Treatment Plan
Your doctor will should want to start treatment right after you’re diagnosed. Learn more about what to consider when you…
Stuart Schlossman
See the latest open-label extension data for Ocrevus
Examine 2 years of controlled and 3+ years of open-label extension efficacy and safety data. View in Browser Important Safety Information…
Stuart Schlossman
CMSC INforMS: Use of DMTs Changing ‘Natural History’ of Relapsing MS, Study Says
Thursday, January 2, 2020 – Posted by: Elizabeth Porco Click HERE to Register for the MS Beacon Newsletter People with…
Stuart Schlossman
